Brenus Pharma unveils promising pre-clinical results extrapolating human conditions in major international congresses.
Benoit PINTEUR, (Pharm.D), Co-Founder and Chief Scientific Officer at Brenus Pharma explains: "After testing the STC product on colorectal cancer models in syngeneic immunocompetent mice (in vivo), where results have shown improved overall survival and enhanced immune response with STC-1010, we tested new models (ex vivo, in ovo) to enhance human extrapolation to validate the STC-1010 biological mechanism of action and replicate excellent results on human colorectal cancer models.